Top

Published in:

01-04-2019 | Original Article

Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study

Authors: Roni Nielsen, MD, PhD, Anders Jorsal, MD, PhD, Peter Iversen, MD, PhD, Lars Poulsen Tolbod, MSc, PhD, Kirsten Bouchelouche, MD, DMSc, Jens Sørensen, MD, DMSc, Hendrik Johannes Harms, MSc, PhD, Allan Flyvbjerg, MD, DMSc, Lise Tarnow, MD, DMSc, Caroline Kistorp, MD, PhD, Ida Gustafsson, MD, PhD, Hans Erik Bøtker, MD, DMSc, Henrik Wiggers, MD, DMSc

Published in: Journal of Nuclear Cardiology | Issue 2/2019

Abstract

Background

The glucagon-like peptide-1 analog liraglutide increases heart rate and may be associated with more cardiac events in chronic heart failure (CHF) patients. We studied whether this could be ascribed to effects on myocardial glucose uptake (MGU), myocardial blood flow (MBF) and MBF reserve (MFR).

Methods and Results

CHF patients with left ventricular ejection fraction ≤45% and without type 2 diabetes were randomized to liraglutide (N = 18) 1.8 mg once daily or placebo (N = 18) for 24 weeks in a double-blinded design. Changes in MGU during an oral glucose tolerance test (OGTT) and changes in MBF and MFR from baseline to follow-up were measured quantitatively by ¹⁸F-FDG and ¹⁵O-H₂O positron emission tomography. Compared with placebo, liraglutide reduced weight (P = 0.03), HbA1c (P = 0.03) and the 2-hour glucose value during the OGTT (P = 0.004). Despite this, changes in MGU (P = 0.98), MBF (P = 0.76) and MFR (P = 0.89) from baseline to follow-up did not differ between groups. Furthermore, there was no association between the level of insulin resistance at baseline and changes in MGU in patients treated with liraglutide.

Conclusion

Liraglutide did not affect MGU, MBF, or MFR in non-diabetic CHF patients. Any potential increase in cardiac events in these patients seems not to involve changes in MGU, MBF, or MFR.

Trial Registration

Trial registry: http://www.ClinicalTrials.org. Identifier: NCT01472640. Url: https://clinicaltrials.gov/ct2/show/NCT01472640?term=NCT01472640&rank=1

Egan JM, Meneilly GS, Habener JF, Elahi D. Glucagon-like peptide-1 augments insulin-mediated glucose uptake in the obese state. J Clin Endocrinol Metab. 2002;87:3768-73.CrossRefPubMed

Bhashyam S, Fields AV, Patterson B, Testani JM, Chen L, Shen YT, et al. Glucagon-like peptide-1 increases myocardial glucose uptake via p38 MAP kinase mediated, nitric oxide dependent mechanisms in conscious dogs with dilated cardiomyopathy/clinical perspective,Circulation. Heart Fail. 2010;3:512-21.CrossRef

Dokken BB, Hilwig WR, Teachey MK, Panchal RA, Hubner K, Allen D, et al. Glucagon-like peptide-1 (GLP-1) attenuates post-resuscitation myocardial microcirculatory dysfunction. Resuscitation. 2010;81:755-60.CrossRefPubMed

Zhao T, Parikh P, Bhashyam S, Bolukoglu H, Poornima I, Shen YT, et al. Direct effects of glucagon-like peptide-1 on myocardial contractility and glucose uptake in normal and postischemic isolated rat hearts. J Pharmacol Exp Ther. 2006;317:1106-13.CrossRefPubMed

Gejl M, Lerche S, Mengel A, Møller N, Bibby BM, Smidt K, et al. Influence of GLP-1 on myocardial glucose metabolism in healthy men during normo- or hypoglycemia. PLoS ONE. 2014;9:e83758.CrossRefPubMedPubMedCentral

Gejl M, Søndergaard HM, Stecher C, Bibby BM, Møller N, Bøtker HE, et al. Exenatide alters myocardial glucose transport and uptake depending on insulin resistance and increases myocardial blood flow in patients with type 2 diabetes. J Clin Endocrinol Metab. 2012;97(7):E1165-9.CrossRefPubMed

Lepore JJ, Olson E, Demopoulos L, Haws T, Fang Z, Barbour AM, et al. Effects of the novel long-acting GLP-1 agonist, albiglutide, on cardiac function, cardiac metabolism, and exercise capacity in patients with chronic heart failure and reduced ejection fraction. JACC. 2016;4(7):559-66.PubMed

Subaran SC, Sauder MA, Chai W, Jahn LA, Fowler DE, Aylor KW, et al. GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans. Clin Sci (Lond). 2014;127(3):163-70.CrossRef

Moberly SP, Mather KJ, Berwick ZC, Owen MK, Goodwill AG, Casalini ED, et al. Impaired cardiometabolic responses to glucagon-like peptide 1 in obesity and type 2 diabetes mellitus. Basic Res Cardiol. 2013;108(4):1-15.CrossRef

10.

Faber R, Zander M, Pena A, Michelsen MM, Mygind ND, Prescott E. Effect of the glucagon-like peptide-1 analogue liraglutide on coronary microvascular function in patients with type 2 diabetes - a randomized, single-blinded, cross-over pilot study. Cardiovasc Diabetol. 2015;14:41.CrossRefPubMedPubMedCentral

11.

Jorsal A, Kistorp C, Holmager P, Tougaard RS, Nielsen R, Hänselmann A, et al. Effect of liraglutide, a glucagon-like peptide-1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE) - a multicentre, double-blind, randomised, placebo-controlled trial. Eur J Heart Fail. 2016;19(1):69-77.CrossRefPubMed

12.

Margulies KB, Hernandez AF, Redfield MM. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: A randomized clinical trial. JAMA. 2016;316:500-8.CrossRefPubMedPubMedCentral

13.

Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-22.CrossRefPubMedPubMedCentral

14.

Kofoed K, Carstensen S, Hove J, Freiberg J, Bangsgaard R, Holm S, et al. Low whole-body insulin sensitivity in patients with ischaemic heart disease is associated with impaired myocardial glucose uptake predictive of poor outcome after revascularisation. Eur J Nucl Med. 2002;29(8):991-8.CrossRef

15.

Majmudar MD, Murthy VL, Shah RV, Kolli S, Mousavi N, Foster C, et al. Quantification of coronary flow reserve in patients with ischaemic and non-ischaemic cardiomyopathy and its association with clinical outcomes. Eur Heart J. 2015;16(8):900-9.

16.

Jorsal A, Wiggers H, Holmager P, Nilsson B, Nielsen R, Boesgaard TW, et al. A protocol for a randomised, double-blind, placebo-controlled study of the effect of LIraglutide on left VEntricular function in chronic heart failure patients with and without type 2 diabetes (The LIVE Study). BMJ Open. 2014;4:e004885.CrossRefPubMedPubMedCentral

17.

Nielsen R, Nørrelund H, Kampmann U, Kim WY, Ringgaard S, Schär M, et al. Failing heart of patients with type 2 diabetes mellitus can adapt to extreme short-term increases in circulating lipids and does not display features of acute myocardial lipotoxicity. Circulation. 2013;6:845-52.PubMed

18.

Wiggers H, Bøttcher M, Nielsen TT, Gjedde A, Bøtker HE. Measurement of myocardial glucose uptake in patients with ischemic cardiomyopathy: Application of a new quantitative method using regional tracer kinetic information. J Nucl Med. 1999;40:1292-300.PubMed

19.

Harms H, Knaapen P, de Haan S, Halbmeijer R, Lammertsma A, Lubberink M. Automatic generation of absolute myocardial blood flow images using [15O]H2O and a clinical PET/CT scanner. Eur J Nucl Med Mol Imaging. 2011;38(5):930-9.CrossRefPubMedPubMedCentral

20.

Rischpler C, Langwieser N, Souvatzoglou M, Batrice A, van Marwick S, Snajberk J, et al. PET/MRI early after myocardial infarction: Evaluation of viability with late gadolinium enhancement transmurality vs. 18F-FDG uptake. Eur Heart J. 2015;16:661-9.

21.

Nielsen R, Jorsal A, Iversen P, Tolbod L, Bouchelouche K, Sørensen J, et al. Heart failure patients with prediabetes and newly diagnosed diabetes display abnormalities in myocardial metabolism. J Nucl Cardiol. 2016;. doi:10.1007/s12350-016-0622-0.CrossRefPubMed

22.

Knaapen P, Boellaard R, Götte MJW, Dijkmans PA, van Campen LMC, de Cock CC, et al. Perfusable tissue index as a potential marker of fibrosis in patients with idiopathic dilated cardiomyopathy. J Nucl Med. 2004;45(8):1299-304.PubMed

23.

Marinho NVS, Keogh BE, Costa DC, Lammerstma AA, Ell PJ, Camici PG. Pathophysiology of chronic left ventricular dysfunction: New insights from the measurement of absolute myocardial blood flow and glucose utilization. Circulation. 1996;93:737-44.CrossRefPubMed

24.

Kaufmann PA, Gnecchi-Ruscone T, Yap JT, Rimoldi O, Camici PG. Assessment of the reproducibility of baseline and hyperemic myocardial blood flow measurements with 15O-labeled water and PET. J Nucl Med. 1999;40(11):1848-56.PubMed

25.

Boudina S, Abel ED. Mitochondrial uncoupling: A key contributor to reduced cardiac efficiency in diabetes. Physiology. 2006;21:250-8.CrossRefPubMed

26.

Nikolaidis LA, Elahi D, Shen YT, Shannon RP. Active metabolite of GLP-1 mediates myocardial glucose uptake and improves left ventricular performance in conscious dogs with dilated cardiomyopathy. Am J Physiol. 2005;289:H2401-8.

27.

Vyas AK, Yang KC, Woo D, Tzekov A, Kovacs A, Jay PY, et al. Exenatide improves glucose homeostasis and prolongs survival in a murine model of dilated cardiomyopathy. PLoS ONE. 2011;6(2):e17178.CrossRefPubMedPubMedCentral

28.

Aravindhan K, Bao W, Harpel MR, Willette RN, Lepore JJ, Jucker BM. Cardioprotection resulting from glucagon-like peptide-1 administration involves shifting metabolic substrate utilization to increase energy efficiency in the rat heart. PLoS ONE. 2015;10(6):e0130894.CrossRefPubMedPubMedCentral

29.

Egstrup M, Schou M, Gustafsson I, Kistorp CN, Hildebrandt PR, Tuxen CD. Oral glucose tolerance testing in an outpatient heart failure clinic reveals a high proportion of undiagnosed diabetic patients with an adverse prognosis. Eur J Heart Fail. 2011;13(3):319-26.CrossRefPubMed

30.

Lautamäki R, Airaksinen KEJ, Seppänen M, Toikka J, Luotolahti M, Ball E, et al. Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease. Diabetes. 2005;54:2787-94.CrossRefPubMed

31.

Marathe CS, Rayner CK, Jones KL, Horowitz M. Relationships between gastric emptying, postprandial glycemia, and incretin hormones. Diabetes Care. 2013;36(5):1396-405.CrossRefPubMedPubMedCentral

32.

Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor dependent and independent pathways. Circulation. 2008;117:2340-50.CrossRefPubMed

33.

Wang D, Luo P, Wang Y, Li W, Wang C, Sun D, et al. Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism. Diabetes. 2013;62:1697.CrossRefPubMedPubMedCentral

34.

Ke J, Liu Y, Yang J, Lu R, Tian Q, Hou W, et al. Synergistic effects of metformin with liraglutide against endothelial dysfunction through GLP-1 receptor and PKA signalling pathway. Sci Rep. 2017;7:41085.CrossRefPubMedPubMedCentral

35.

Bøttcher M, Refsgaard J, Gøtzsche O, Andreasen F, Toftegaard NT. Effect of carvedilol on microcirculatory and glucose metabolic regulation in patients with congestive heart failure secondary to ischemic cardiomyopathy. Am J Cardiol. 2002;89(12):1388-93.CrossRefPubMed

Title: Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study
Authors: Roni Nielsen, MD, PhD
Anders Jorsal, MD, PhD
Peter Iversen, MD, PhD
Lars Poulsen Tolbod, MSc, PhD
Kirsten Bouchelouche, MD, DMSc
Jens Sørensen, MD, DMSc
Hendrik Johannes Harms, MSc, PhD
Allan Flyvbjerg, MD, DMSc
Lise Tarnow, MD, DMSc
Caroline Kistorp, MD, PhD
Ida Gustafsson, MD, PhD
Hans Erik Bøtker, MD, DMSc
Henrik Wiggers, MD, DMSc
Publication date: 01-04-2019
Publisher: Springer International Publishing
Published in: Journal of Nuclear Cardiology / Issue 2/2019
Print ISSN: 1071-3581
Electronic ISSN: 1532-6551
DOI: https://doi.org/10.1007/s12350-017-1000-2

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The STEP trials

Springer Medicine

Effect of liraglutide on myocardial glucose uptake and blood flow in stable chronic heart failure patients: A double-blind, randomized, placebo-controlled LIVE sub-study

Abstract

Background

Methods and Results

Conclusion

Trial Registration

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods and Results

Conclusion

Trial Registration

Please log in to get access to this content

Other articles of this Issue 2/2019

The utility of 82Rb PET for myocardial viability assessment: Comparison with perfusion-metabolism 82Rb-18F-FDG PET

Can FDG-PET imaging play a role in guiding indications to endovascular treatments in patients presenting acute aortic syndromes?

Stress for a stressed out heart: Classic cardiac PET findings in takotsubo cardiomyopathy

Relationship of non-invasive quantification of myocardial blood flow to arrhythmic events in patients with implantable cardiac defibrillators

Anti-inflammatory effect of statin in coronary aneurysms late after Kawasaki disease

Correction to: The effect of beta blocker withdrawal on adenosine myocardial perfusion imaging

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page